Skip to Main Content

Author Details

John W Barrett
University of Western Ontario
1992
117
35
PMIDPaper TitleJournal TitlePublished Year
38059331HPV-negative head and neck cancers with adverse pathological features carry specific molecular changes that are associated with survival.Head Neck2024
35317874Establishment of four head and neck squamous cell carcinoma cell lines: importance of reference DNA for accurate genomic characterisation.J Laryngol Otol2023
38058352Clinical Presentation and Genomic Analysis of HPV-Related Squamous Cell Carcinoma of the Larynx in Two Young Female Patients.Cureus2023
37580614In vivo tracking of adenoviral-transduced iron oxide-labeled bone marrow-derived dendritic cells using magnetic particle imaging.Eur Radiol Exp2023
37778229Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.Oral Oncol2023
34602108The prevalence of human papillomavirus in paediatric tonsils in Southwestern Ontario.J Laryngol Otol2022
36442320Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.EBioMedicine2022
35950764The HPV Induced Cancer Resource (THInCR): a Suite of Tools for Investigating HPV-Dependent Human Carcinogenesis.mSphere2022
35919862Proteome and phosphoproteome signatures of recurrence for HPV<sup>+</sup> head and neck squamous cell carcinoma.Commun Med (Lond)2022
35227792The Impact of Surgical Resectability on Outcomes for Patients Undergoing Primary Radiation Treatment for Human Papillomavirus-Related Oropharyngeal Cancer.Int J Radiat Oncol Biol Phys2022
35187756Tumor molecular differences associated with outcome disparities of Black patients with head and neck cancer.Head Neck2022
34475951Detection of Circulating Tumor DNA in Patients with Thyroid Nodules.Int J Endocrinol2021
33824664Does HPV Subtype Predict Outcomes in Head and Neck Cancers?Int J Otolaryngol2021
33588906Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.Infect Agent Cancer2021
33725617All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.Oral Oncol2021
347714773p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset.Cancers (Basel)2021
32146388Sex disparities in head &amp; neck cancer driver genes: An analysis of the TCGA dataset.Oral Oncol2020
31968678Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers.Cancers (Basel)2020
31864959Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.Oral Oncol2020
31804024Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.Mol Oncol2020
33059733TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.J Exp Clin Cancer Res2020
33168055Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution.Radiat Oncol2020
33396315Analysis of the TCGA Dataset Reveals that Subsites of Laryngeal Squamous Cell Carcinoma are Molecularly Distinct.Cancers (Basel)2020
32970704Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.PLoS One2020
32828022Chromosome 3p loss in the progression and prognosis of head and neck cancer.Oral Oncol2020
32178827DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.Methods Enzymol2020
30468243A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.Int J Cancer2019
31844556Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival.Cancers Head Neck2019
31394808High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells.Cancers (Basel)2019
31393061Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.Mol Oncol2019
30626742Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status.JCI Insight2019
29378664The prevalence of human papillomavirus in pediatric tonsils: a systematic review of the literature.J Otolaryngol Head Neck Surg2018
29899842High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.Oncotarget2018
30115483ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.Oral Oncol2018
30288365Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.Oncoimmunology2018
30419054Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.PLoS One2018
28067913Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.Nat Genet2017
29069809Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin.Oncotarget2017
29069723Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.Oncotarget2017
28854921Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.BMC Cancer2017
28891951Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection.Viruses2017
26271341Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.Pathol Oncol Res2016
24725020Defining the genomic landscape of head and neck cancers through next-generation sequencing.Oral Dis2015
27119108Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis.Mol Ther Oncolytics2015
23942307Vaccinia virus outperforms a panel of other poxviruses as a potent oncolytic agent for the control of head and neck squamous cell carcinoma cell lines.Intervirology2014
25428177Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.BMC Pharmacol Toxicol2014
25276134Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.J Oncol2014
25038405The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.Virus Res2014
25027574Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer.J Clin Virol2014
24403595The human papillomavirus E7 proteins associate with p190RhoGAP and alter its function.J Virol2014
  • 1 - 50 of 117

Recommended Authors

Icahn School of Medicine at Mount Sinai
Career Start Year 2013
Number of shared co-authors 0
University of Ottawa
Career Start Year 2012
Number of shared co-authors 4
David Geffen School of Medicine, University of California los angeles
Career Start Year 2009
Number of shared co-authors 1
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 0
Ottawa Hospital Research Institute
Career Start Year 2006
Number of shared co-authors 3
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Career Start Year 2005
Number of shared co-authors 0
University of California san francisco
Career Start Year 2003
Number of shared co-authors 0
Minnesota Supercomputing Institute, University of Minnesota
Career Start Year 2003
Number of shared co-authors 0
University of Toledo
Career Start Year 2002
Number of shared co-authors 0
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 0
Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University
Career Start Year 1999
Number of shared co-authors 0
MRC - University of Glasgow Centre for Virus Research, University of Glasgow
Career Start Year 1998
Number of shared co-authors 0
Pondicherry University
Career Start Year 1997
Number of shared co-authors 0
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 1997
Number of shared co-authors 0
Stanford University School of Medicine
Career Start Year 1996
Number of shared co-authors 0
University of Edinburgh
Career Start Year 1996
Number of shared co-authors 0
Cancer Research Institute, Central South University
Career Start Year 1995
Number of shared co-authors 0
University of California San Diego
Career Start Year 1994
Number of shared co-authors 0
University of California Berkeley
Career Start Year 1993
Number of shared co-authors 0
Harvard Medical School, Brigham and Women's Hospital
Career Start Year 1992
Number of shared co-authors 1
University of California los angeles
Career Start Year 1992
Number of shared co-authors 1
The Children's Hospital of Philadelphia
Career Start Year 1992
Number of shared co-authors 1
Altius Institute for Biomedical Sciences
Career Start Year 1990
Number of shared co-authors 1
University of North Carolina at Chapel Hill
Career Start Year 1986
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1986
Number of shared co-authors 0
David Geffen School of Medicine at university of california los angeles
Career Start Year 1984
Number of shared co-authors 1
University of Texas Medical Branch
Career Start Year 1983
Number of shared co-authors 0
J. Craig Venter Institute
Career Start Year 1983
Number of shared co-authors 0
University of Victoria
Career Start Year 1979
Number of shared co-authors 0
Tulane University School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

University of Western Ontario
Co-authored papers 56
University of Western Ontario
Co-authored papers 49
Schulich School of Medicine & Dentistry, Western University
Co-authored papers 37
Schulich School of Medicine & Dentistry, Western University, Victoria Hospital
Co-authored papers 35
University of Western Ontario
Co-authored papers 29
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 26
University of California los angeles
Co-authored papers 21
School of Public Policy at the University of Calgary
Co-authored papers 17
Western University
Co-authored papers 15
Southern Illinois University School of Medicine
Co-authored papers 14
Schulich School of Medicine and Dentistry, University of Western Ontario
Co-authored papers 14
Western University
Co-authored papers 13
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 12
Moffitt Cancer Center
Co-authored papers 11
Western University, Lawson Health Research Institute
Co-authored papers 11
University of Western Ontario
Co-authored papers 10
University of Western Ontario
Co-authored papers 10
McMaster Immunology Research Centre, McMaster University
Co-authored papers 10
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 9
University of California at Davis School of Medicine
Co-authored papers 9
Schulich School of Medicine & Dentistry, Western University
Co-authored papers 8
Zhongnan Hospital of Wuhan University
Co-authored papers 8
University of Western Ontario
Co-authored papers 8
Queen's University
Co-authored papers 7
Western University
Co-authored papers 7
University Health Network
Co-authored papers 7
Ottawa Hospital Research Institute
Co-authored papers 6
Schulich School of Medicine & Dentistry, Western University
Co-authored papers 6
University of Toronto
Co-authored papers 6
Western University
Co-authored papers 6